Hoth Therapeutics, Inc. (RKTO) Stock Analysis & Investment Frameworks
Hoth Therapeutics, Inc. (RKTO) stock analysis on Invetso. Review Hoth Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Hoth Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Technology
- Industry: Software - Infrastructure
- Country: US
Hoth Therapeutics, Inc. Key Financial Metrics
- Market Cap: $11.32M
- Revenue: $N/A
- ROE: -199.23%
- ROIC: -160.57%
- Dividend Yield: N/A
About Hoth Therapeutics, Inc.
Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure. It also develops AI chip and memory hardware engineered for orbital and high-radiation environments, including next generation nanomagnetic AI chip technology. It offers semiconductor infrastructure built around nanomagnetic, and spintronic computing technologies designed to address these constraints at the hardware level. It also offers non-volatile nanomagnetic matrix multiplier architecture for machine learning and AI acceleration and spintronic memory technology with potential applications across defense systems, autonomous platforms, resilient edge compute, and radiation-tolerant space computing. The company was formerly known as Hoth Therapeutics, Inc. and changed its name to Rocket One Inc. in May 2026. The company was incorporated in 2017 and is based in Hoboken, New Jersey.
Hoth Therapeutics, Inc. Investment Frameworks
Invetso analyzes Hoth Therapeutics, Inc. (RKTO) across the following frameworks:
- Hoth Therapeutics, Inc. 10Y Growth Potential
- Hoth Therapeutics, Inc. Scenario Analysis
- Hoth Therapeutics, Inc. Risks & Opportunities
- Hoth Therapeutics, Inc. Economic Moat
- Hoth Therapeutics, Inc. Business Model
- Hoth Therapeutics, Inc. Management
- Hoth Therapeutics, Inc. SWOT Analysis
- Hoth Therapeutics, Inc. Porter's 5 Forces
- Hoth Therapeutics, Inc. PESTLE Analysis
- Hoth Therapeutics, Inc. ESG Analysis

